Bristol-myers Squibb Compnay

Matthew D Hill

Haiquan Fang

Andrew P Degnan

John E Macor

F Christopher Zusi

James H Cook, Ii

Richard Eric Olson

Wayne D Vaccaro

John E Starrett, Jr

Derek J Norris

Wen-Ching Han

Ivar M McDonald

George V Delucca

Dalton King

Claude A Quesnelle

Christiana I Iwuagwu

Godwin Kwame Kumi

Robert A Mate

Nenghui Wang

William D Schmitz

Hong Huang

Mikkel V DeBenedetto

Ashvinikumar V Gavai

Yan Chen

Joanne J Bronson

John S Tokarski

Mark D Wittman

Fukang Yang

Harold A Mastalerz

Michael Frederick Parker

Francis Lee

Lalgudi S Harikrishnan

Bradley C Pearce

Mikkel V Debenedetto

Daniel O'Malley

Bireshwar Dasgupta

Patrice Gill

Guifen Zhang

George V De Lucca

Sunil Kumar Mandal

Rex Denton

Jeffrey A Deskus

Erika M V Araujo

Kimberley A Lentz

Darrell Maxwell

Daniel O'malley

Francis Y Lee

John E Starrett

Jr John E Starrett

James H Cook Ii

James H Ii Cook

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer. 

Isofuranone compounds useful as HPK1 inhibitors

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Tricyclic compounds as anticancer agents

There are disclosed a series of quinuclidines having the Formula (I), which bind to the nicotinic &#x3b1;7 receptor and may be useful for the treatment of disorders of the central nervous system. 

Quinuclidine compounds as &#x3b1;-7 nicotinic acetylcholine receptor ligands

The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Oxazolidinones as modulators of mGluR5

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo [3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Growing community of inventors

Wallingford, CT, United States of America

Matthew D Hill